Alkem Laboratories Overview

  • Year Founded
  • 1973

Year Founded

  • Status
  • Public

  • Employees
  • 23,386

Employees

  • Stock Symbol
  • ALKEM

Stock Symbol

  • Investments
  • 18

  • Share Price
  • $55.05
  • (As of Thursday Closing)

Alkem Laboratories General Information

Description

Alkem Laboratories Ltd is a diversified healthcare company engaged in the pharmaceutical business with operations. The Company is engaged in the development, manufacture, and sale of pharmaceutical products. It operates in one reportable business segment, Pharmaceuticals. Its operations include Domestic Pharma (Branded & Trade Generics, ActivLife and Alkem), Biotech (Biosimilars & Bio-CDMO), MedTech and Activa, and International Business. It focuses on chronic therapies, including anti-diabetes, dermatology, urology, and inhaled chronic respiratory. It caters to pharmaceutical firms, distributors, wholesalers, pharmacy chains, hospitals, and other healthcare-related institutional customers across domestic and international markets. It generates the maximum revenue from the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Devashish Building, Alkem House
  • Senapati Bapat Road, Lower Parel
  • Mumbai, 400013
  • India
+91 022
Primary Industry
Pharmaceuticals
Stock Exchange
NSE
Vertical(s)
Corporate Office
  • Devashish Building, Alkem House
  • Senapati Bapat Road, Lower Parel
  • Mumbai, 400013
  • India
+91 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alkem Laboratories Stock Performance

As of 19-Nov-2026, Alkem Laboratories’s stock price is $55.05. Its current market cap is $6.58B with 120M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$55.05 $55.87 $51.01 - $65.83 $6.58B 120M 148K $1.87

Alkem Laboratories Financials Summary

As of 30-Sep-2026, Alkem Laboratories has a trailing 12-month revenue of $1.69B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 6,272,506 6,438,544 6,479,174 6,846,847
Revenue 1,685,984 1,644,604 1,514,314 1,502,580
EBITDA 389,780 336,935 308,980 258,785
Net Income 223,016 260,491 256,096 216,918
Total Assets 2,400,765 2,212,230 2,068,184 1,867,640
Total Debt 240,462 216,969 161,435 170,086
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alkem Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alkem Laboratories‘s full profile, request access.

Request a free trial

Alkem Laboratories Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alkem Laboratories Ltd is a diversified healthcare company engaged in the pharmaceutical business with operations. The C
Pharmaceuticals
Mumbai, India
23,386 As of 2026

Ahmedabad, India
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alkem Laboratories Competitors (60)

One of Alkem Laboratories’s 60 competitors is Torrent Pharmaceuticals, a Corporation company based in Ahmedabad, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Torrent Pharmaceuticals Corporation Ahmedabad, India
Cipla Corporation Mumbai, India
Mankind Pharma Formerly PE-Backed New Delhi, India
Marksans Pharma Corporation Mumbai, India
Ajanta Pharma Corporation Mumbai, India
You’re viewing 5 of 60 competitors. Get the full list »

Alkem Laboratories Patents

Alkem Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240374527-A1 Pharmaceutical composition comprising lumateperone Pending 08-May-2023
WO-2024079748-A1 Novel salts of aramchol and process thereof Inactive 13-Oct-2022
EP-4577201-A1 Mesdopetam compositions Inactive 24-Aug-2022
US-20260053759-A1 Mesdopetam compositions Inactive 24-Aug-2022
WO-2024042540-A1 Mesdopetam compositions Inactive 24-Aug-2022 A61K31/145
To view Alkem Laboratories’s complete patent history, request access »

Alkem Laboratories Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alkem Laboratories Investments & Acquisitions (18)

Alkem Laboratories’s most recent deal was a Joint Venture with Alkem Pharma Company. The deal was made on 08-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alkem Pharma Company 08-Nov-2026 Joint Venture Pharmaceuticals
HaystackAnalytics 13-Mar-2026 Later Stage VC Decision/Risk Analysis
Adroit Biomed 23-Apr-2025 Merger/Acquisition Personal Products
Bombay Ortho Industries 16-Apr-2025 Merger/Acquisition Other Devices and Supplies
Sahajanand Medical Technologies 15-Oct-2024 Merger/Acquisition Surgical Devices
You’re viewing 5 of 18 investments and acquisitions. Get the full list »

Alkem Laboratories ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

29.29 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Alkem Laboratories’s complete esg history, request access »

Alkem Laboratories Exits (1)

Alkem Laboratories’s most recent exit was on 28-Aug-2017 from Medlife. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Medlife 28-Aug-2017 Completed
To view Alkem Laboratories’s complete exits history, request access »

Alkem Laboratories Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Adroit Biomed Mumbai, India 2012
S&b Pharma Azusa, CA 2012
Pharmacor Sydney, Australia 2007
Bombay Ortho Industries Rajkot, India 2002
Ascend Laboratories Bedminster, NJ 2000

Alkem Laboratories FAQs

  • When was Alkem Laboratories founded?

    Alkem Laboratories was founded in 1973.

  • Where is Alkem Laboratories headquartered?

    Alkem Laboratories is headquartered in Mumbai, India.

  • What is the size of Alkem Laboratories?

    Alkem Laboratories has 23,386 total employees.

  • What industry is Alkem Laboratories in?

    Alkem Laboratories’s primary industry is Pharmaceuticals.

  • Is Alkem Laboratories a private or public company?

    Alkem Laboratories is a Public company.

  • What is Alkem Laboratories’s stock symbol?

    The ticker symbol for Alkem Laboratories is ALKEM.

  • What is the current stock price of Alkem Laboratories?

    As of 19-Nov-2026 the stock price of Alkem Laboratories is $55.05.

  • What is the current market cap of Alkem Laboratories?

    The current market capitalization of Alkem Laboratories is $6.58B.

  • What is Alkem Laboratories’s current revenue?

    The trailing twelve month revenue for Alkem Laboratories is $1.69B.

  • Who are Alkem Laboratories’s competitors?

    Torrent Pharmaceuticals, Cipla, Mankind Pharma, Marksans Pharma, and Ajanta Pharma are some of the 60 competitors of Alkem Laboratories.

  • What is Alkem Laboratories’s annual earnings per share (EPS)?

    Alkem Laboratories’s EPS for 12 months was $1.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process